Objective: Olanzapine and risperidone are members of the atypical antipsychotic family. Even though they are widely used for the treatment of a broad range of symptoms and disorders in psychiatric practice, their effects on kidney are little known. Nevertheless, the toxic features of these medicines on the tissues, organs or systems other than the kidneys have been demonstrated previously. For these reasons, we aimed to evaluate the effects of long-term administration of low-and high-doses of olanzapine and risperidone on rat kidneys in the present study. Methods: Twenty five rats were divided into 5 groups equally: a control group (CG), a low-dose olanzapine group (LOG), a high-dose olanzapine group (HOG), a low-dose risperidone group (LRG), and a high-dose risperidone group (HRG). Olanzapine in doses of 0.5 and 2.5 mg/kg daily for 6 weeks were intraperitoneally injected into the LOG and HOG, respectively. Similarly, risperidone in doses of 0.5 and 1 mg/kg daily for 6 weeks were intraperitoneally injected into the LRG and HRG, respectively. Same volume and dosages of saline (0.9% NaCl) were given to the CG during the same period. At the end of the experiment, the kidneys were dissected out and evaluated histopathologically. Results: Although there were any abnormalities in the LOG, it was determined significant nephrotoxic effects, including losing regularities in both tubular and glomerular structure of kidneys, focal necrosis in some area of renal cortex and medulla, cells with pyknotic nuclei and eosinophilic cytoplasm in both glomerular capillaries and mesangium, an increase in thickness of basal membrane of intraglomerular capillary, especially in parietal layer of Bowman's capsule, and in some fields, abnormalities caused by the loss of tubule cells, such as hydropic vacuolization and eosinophilic accumulations in the HOG, LRG, and HRG. Conclusion: Albeit it has been hypothesized that these nephrotoxic effects are due to the oxidative stress and mitochondrial dysfunction associated antipsychotic treatment, the definite mechanisms of the nephrotoxicity continue uncertain. On the other hand, nephrotoxicity that presents with cells and casts in the urine, oliguria, proteinuria, elevated serum creatinine, and elevated urea may occur easily in some individuals and these agents should be used cautiously, particularly in patients with renal disease. Because some toxicity here is dose-dependent, there might be an advantage of preferring minimum therapeutic doses with chronic administration to decrease their side effects on the kidney in these special conditions. However, further research is surely needed to study the causal relationship between atypical antipsychotic use and nephrotoxicity.
INTRODUCTION
Antipsychotic drugs have been grouped according to both pattern of clinical action and mechanism of action. The original antipsychotic drugs such as chlorpromazine and haloperidol have been called typical or first generation. They cause both antipsychotic actions and many side effects (extrapyramidal and hormonal) that are ascribed to their high affinity dopamine D 2 receptor antagonism. Drugs such as olanzapine and risperidone were then developed that avoided the neurological and endocrine side effects (atypical or second generation antipsychotics) (1) . Olanzapine is an antagonist of the D 1 and D 2 dopamine, muscarinic, cholinergic, and 5-HT 2A serotonin receptors and is used in the management of both positive and negative symptoms of schizophrenia (2) . Similarly, risperidone has a high binding affinity for both dopamine D 2 and serotonin 5-HT 2 receptors and has also proven efficacy in the treatment of schizophrenia with both positive and negative symptomatology (3) .
The cytotoxic properties of the typical antipsychotic drugs are well known. Chlorpromazine, fluphenazine, trifluoperazine, and related drugs have been reported to inhibit proliferation in a variety of cell lines and to alter cell morphology (4) . Similarly, haloperidol, another typical antipsychotic agent, has been shown to be hepato-(5) and nephrotoxic (6) in rats, especially at high doses. The results of the latter study suggest that there is a significant relationship between haloperidol treatment and structural changes in the kidneys such as tubular deformations, prominent dilatation of the renal vessels and tubules, enlarged glomeruli, and glomerular basal membrane thickening. These structural abnormalities may cause changes in renal morphometry. Finally, the findings of the above-mentioned work clarify that the stereological and histopathological reasons underlying dose-dependent renal injury are associated with chronic administration of haloperidol. There have also been previous suggestions that these cytotoxic effects of the typical antipsychotic drugs are responsible for some of the adverse effects of these medications in patients, particularly the movement disorders and tardive dyskinesia. In contrast, the newer atypical drugs produce significantly fewer extrapyramidal symptoms (7) . Although these data might be interpreted to mean that the atypical drugs are less toxic for cells, which tends to support a relationship between in vitro toxicity and in vivo side effects, there are also adverse effects reported for these compounds. Therefore, the cytotoxic and cytoprotective effects of the atypical antipsychotic agents, including olanzapine and risperidone, are being intensively investigated (8, 9, 10) .
Although these atypical antipsychotic drugs have produced countless benefits for patients, some side effects are inevitable. For example, in other experimental studies performed in our laboratory, side effects of olanzapine (11) and risperidone (12) on hepatocytes have been reported. In addition, some researchers have demonstrated side-effects related to metabolic dysfunction (13, 14) . In addition to other side effects such as extrapyramidal effects and tardive dyskinesia (via blockade of dopamine D 2 receptors) or anticholinergic effects and memory impairment (via blockade of muscarinic receptors) (15) , the effectiveness and/or adverse effects of olanzapine and risperidone, as well as other atypical antipsychotic drugs, have been examined in the literature since liver metabolism and excretion of metabolic products by the kidney may alter absorption, metabolism, and excretion (16, 17) .
Even though some recent workhas demonstrated toxic effects of these agents in different tissues of both laboratory animals and human beings (e.g. changes in liver function tests and weight gain), nephrotoxicity of this class of drugs is not common (18, 19) and no systematic data on the nephrotoxic effects of olanzapine and risperidone have been published. Therefore, we aimed to examine possible histopathological dose-dependent toxic effects of olanzapine and risperidone on rat kidneys.
MATERIALS and METHODS

Animals
All experiments were performed with 25 adult male Wistar Albino rats, each weighing 200-210 g. They were obtained from Ataturk University Experimental Animal Laboratory of Medicinal and Experimental Application and Research Center (ATADEM). Care of the rats was in accordance with the ILAR/NRC Guide for the Care and Use of Laboratory Animals (2010 edition), and all procedures were also approved by the Ataturk University Local Animal Care Committee. The Ethics Committee of the Ataturk University Medical Faculty approved the whole study protocol. The rats were housed in standard plastic cages on sawdust bedding in an air-conditioned room at 22.0±1.0°C under controlled lighting (14 h light/10 h dark cycle). Standard rat chow and tap water were given ad libitum. The rats were divided into five groups with each group containing five rats: a control group (CG), a low-dose olanzapine group (LOG), a high-dose olanzapine group (HOG), a low-dose risperidone group (LRG), and a high-dose risperidone group (HRG). The groups were kept in different cages.
Drug and Drug Administration
Olanzapine which was purchased from Eli Lilly Turkey, Istanbul, Turkey was dissolved in normal saline (0.9% NaCl) and given intraperitoneally (11, 20) once per day for 6 weeks (2 and 4 mg/kg/day for the LOG and HOG, respectively). For the present study, olanzapine dosages were chosen as equivalent to the highest dosages used in humans (0.5 and 2.5 mg/kg/day) (11, 21) .
Risperidone which was bought from Janssen Turkey, Istanbul, Turkey was also dissolved in normal saline (0.9% NaCl) and given intraperitoneally (12, 20) in doses once a day for 6 weeks (0.5 and 1 mg/kg/day for the LRG and HRG, respectively). Risperidone at doses of 1 mg/kg were chosen as equivalent to the highest dosage used in human beings (12, 22) .
The same volumes of normal saline (0.9% NaCl) were given to the CG (12).
Tissue Preparation Processes
Following the aforementioned period, the rats were killed by an overdose of a general anesthetic (thiopental sodium, 50 mg/kg). The rats were bled before organ sampling, and then the kidneys were dissected out immediately and transferred into a 10% formaldehyde solution for light microscopy.
Conventional Light Microscopy by Hematoxylin-Eosin (H&E) and Periodic Acid-Schiff (PAS)
On the following day, the kidney samples were placed into the same fixative (buffered formalin) for 24 h at room temperature. Subsequently the samples were prepared according to conventional light microscopic technique; i.e. they were dehydrated in a graded alcohol series, embedded in paraffin wax, and serially sectioned using a Leica RM2125RT microtome (Leica Microsystems, Wetzlar, Germany). Each paraffin block was serially cut into 5 µm-thick sections. Approximately 100 sections were obtained from each tissue block, and these sections were then stained with hematoxylineosin and periodic acid-Schiff. All sections from renal cortex and medulla were studied and photographed by a light photomicroscope (Olympus BH 40) (12, 23) .
RESULTS
Control Group (CG)
The renal cortex ( Figure 1A Nephrons, which consist of one renal corpuscle that has several parts and its associated tubule and are the functional unit of the kidney, were normal ( Figure 1C H&E , C PAS , E H&E , and F PAS ). No abnormal changes were detected in distinct parts of the renal corpuscle such as Bowman's capsule that is the outer epithelial wall of the corpuscle ( Figure 1B H&E and E H&E ), Bowman's space that is the space lying within Bowman's capsule, and the glomerulus that 
Low-Dose Olanzapine Group (LOG)
In this group, there were no significant changes. Histopathological findings were quite similar to controls except for moderate dilatation of the glomerular capillaries ( Figure 2F 
High-Dose Olanzapine (HOG) and Low/ High-Dose Risperidone (LDR/HDR) Groups
Histopathological findings obtained from the highdose olanzapine and low/high-dose risperidone groups were similar to each other but different from the control and low-dose olanzapine groups. In the former groups, the following changes were determined:
-loss of regularity in both the tubular ( Figure 3C 
DISCUSSION
Our rationale for conducting the present research was based upon the hypothesis that if the cytotoxicity of olanzapine and risperidone is still controversial, they also might have toxic effects on the survival of rat kidney cells. Therefore, we evaluated and compared the impacts of different concentrations of olanzapine and risperidone. Although there were no abnormalities in the LOG, it was determined that there was significant nephrotoxicity in the HOG, LRG, and HRG. To our knowledge, this is also the first histological study examining the cytotoxic effects of both olanzapine and risperidone on the renal cells of rats. We did not have an opportunity to compare our results with previous research. However, some toxicological studies have described toxic features of these drugs on tissues, organs, or systems other than the kidneys.
In this context, Odaci et al. (11) reported that either low or high doses of olanzapine damaged rat livers at a cellular level in their histological and stereological study investigating the cytotoxic effects of olanzapine on the hepatocytes of male Wistar Albino rats. They found a significant difference in the total number of hepatocytes in rat livers between the CG, LOG, and HOG. The significant difference in the number of hepatocytes between the CG and LOG was an unexpected result for their study group because there had been no suggestion that a low-dose olanzapine treatment would decrease the number of hepatocytes in rat livers. Additionally, they did not have an explanation for this result that agrees with the results of the current literature. More recently, Weston-Green et al. (13) investigated how olanzapine might induce metabolic dysfunctional side-effects such as weight gain, obesity, and diabetes dose-dependently in rats. They showed that olanzapine increased body weight, food intake, and feeding efficiency with no effect on water intake, subcutaneous inguinal and intra-abdominal perirenal fat in female Sprague-Dawley rats. On the contrary, olanzapine decreased insulin and locomotor activity in the open field arena in their study. The animal model used here appears to mimic some aspects of clinical experience. Similarly, Muller et al. (24) evaluated the interactions of chronic treatment with olanzapine and a cafeteria diet on metabolic parameters in male Wistar rats. They showed that chronic olanzapine treatment caused an increase in fat pad weight. Unfortunately, this change was found to be putatively involved in the etiology of many metabolic diseases previously. As a summary, chronic olanzapine administration seems to be related with hepatopathy and metabolic syndrome in rats.
Similar results have been encountered in some studies connected with risperidone toxicity. For instance, Bogdan et al. (25) examined the possible hepatotoxicity of some antipsychotics, including risperidone, in adult male Wistar rats. Although they did not provide detailed information about the dose, route, and duration of the antipsychotic administration , they reported granulo-vacuolar dystrophy in the parenchyma of hepatocytes of rats treated with risperidone. As a consequence, this study revealed the possible toxicity of the second generation antipsychotic risperidone on the liver. Correspondingly, Lauressergues et al. (14) inspected the effects of chronic treatment with risperidone on body weight, fat accumulation, and liver weight in female mice. They found a significant weight gain associated with an increase of liver and adipose tissue weight with the treatment with risperidone. This finding suggests that risperidone could alter lipid metabolism in the liver and induce weight gain. However, Boyda et al. (26) examined the acute effects of both high and low dose risperidone on alterations in glucose and insulin parameters using a rodent model. They established significant doseand time-dependent effects with risperidone on fasting plasma glucose and insulin concentrations, homeostasis model of assessment-insulin resistance values, insulin resistance, and glucose intolerance. Together, these findings indicate that acute administration of risperidone has potent effects on the metabolic regulation of glucose and insulin sensitivities, which may contribute to the metabolic side-effects seen in humans. In conclusion, hepatotoxicity, weight gain, and metabolic disturbances, such as dyslipidemia and hyperglycemia are common side effects of risperidone. The above-mentioned effects were formerly connected to the direct toxic action of these drugs on the living cells of the related organs (e.g. liver and pancreas), but today subcellular and molecular methods have also been used intensively to reveal other possibilities underlying tissue or organ toxicity.
Although the mechanisms of the nephrotoxicity here still remain unclear, it might be hypothesized that oxidative stress and mitochondrial dysfunction associated with antipsychotic treatment might have a dose-dependent or -independent nephrotoxic effect in the pathogenesis of nephrotoxicity. Generation of reactive oxygen species (ROS) such as hydrogen peroxide, superoxide radicals, hydroxyl radicals, and lipid peroxides are known to damage various cellular components, including membrane lipids, proteins and DNA and thereby contribute to cellular dysfunction (12) . There is increasing evidence to indicate that oxidative stress may be the most critical component in the pathophysiology and outcome of toxicities related to antipsychotic treatments. In a previous study, we investigated the effects of long-term and low dose treatment with the typical antipsychotic, haloperidol, and the second generation atypical antipsychotics, risperidone and olanzapine, on the expression of the key antioxidant defense enzymes and lipid peroxidation products in rat plasma; we found that these three antipsychotic drugs generally decreased plasma malondialdehyde levels (27) . Therefore, the side effects associated with chronic treatment may be induced by oxidative cell injury. More recently, Heiser et al. (28) investigated the effects of some antipsychotics, including olanzapine on the formation of ROS in the whole blood of rats by using electron spin resonance spectroscopy. They also incubated the highest concentration of olanzapine with vitamin C to test its protective capacity. Their study demonstrated that olanzapine induces the formation of ROS in the whole blood of rats, which can be reduced by the application of vitamin C. There is also growing evidence that ROS are involved not only in side effects of antipsychotic medications, but also in the pathophysiology of psychiatric disorders such as schizophrenia. Similarly, Shertzer et al. (29) examined the ability of the antioxidant tetrahydroindenoindole (THII) to prevent metabolic changes in mice receiving olanzapine. Olanzapine treatment doubled the high-fat (HF) diet-induced increases in body weight and percent body fat. As increased body fat promotes insulin resistance by a pathway involving oxidative stress, they evaluated production of reactive oxygen and lipid peroxidation in white adipose tissue (WAT). The HF diet caused an increase in lipid peroxidation, NADPHdependent oxygen uptake, and hydrogen peroxide production, which were further exacerbated by olanzapine.
Each of THII, the NADPH oxidase inhibitor, and diphenyleneiodonium chloride abolished oxidative stress in WAT. Finally, they concluded that THII intervenes in the development of obesity and metabolic complications associated with olanzapine treatment. In their classical work, Pillai et al. (30) compared the effect of 90 and 180 day exposure to haloperidol, a representative typical antipsychotic, to exposure to various atypical antipsychotics, including risperidone on the expression of antioxidant defense enzymes and levels of lipid peroxidation in the rat brain. The oxidative membrane damage was assessed by determination of levels of the lipid peroxidation products, hydroxyalkanals (HAEs), in the rat brain. Although risperidone did not show any change in the HAEs levels up to 90 days in contrast to haloperidol, further treatment up to 180 days resulted in significantly increased levels of HAEs. Understanding of long-term treatment effects of risperidone on the oxidative neural cell injury in rats may be important to explain the possible differential mechanisms underlying its long-term clinical and side effect profiles.
On the other hand, the nephrotoxic effects might also be due to the direct action of olanzapine and risperidone on renal mitochondria. Because the kidney contains more mitochondria compared to other organs, the reducing effects of these compounds on mitochondrial functions may also be important in the pathogenesis of nephrotoxicity. Modica-Napolitano et al. (31) tested a series of typical and atypical antipsychotics, including risperidone and olanzapine for effects on integrated bioenergetic functions of isolated rat liver mitochondria in their reference study. They showed that risperidone inhibited NADH-coenzyme Q reductase in freeze-thawed mitochondria, which is a direct measure of complex I enzyme activity. However, the inhibition of NADH-coenzyme Q reductase activity by the atypical antipsychotic risperidone was 2-4 fold less than that for the typical neuroleptics. Olanzapine had only slight effects on NADH-coenzyme Q reductase activity, even at 200 µM. This finding suggests that compromised bioenergetic function may be involved in the cellular pathology underlying nephrotoxicity. In line with the aforementioned work, we did not determine any histopathological changes in the LOG in the present study. Low-dose olanzapine might have not affected the mitochondrial functions in an amount equal to low-dose risperidone. Clinical reflections of mitochondrial dysfunction associated with antipsychotic use have also been shown previously. For instance, Ahn et al. (32) reported an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone. Within 48 hours after discontinuation of the medication, she had complete resolution of psychotic symptoms, fatigue, and psychomotor retardation, and her depression improved. This observation of "on-off" risperidone treatment suggests that risperidone may have worsened both the psychiatric and physical manifestations of the mitochondrial disorder in this patient. These findings are also consistent with recent in vitro literature, which implicate a series of neuroleptic medications with mitochondrial dysfunction.
Although there are no reports about significant nephrotoxicity with both olanzapine and risperidone in the current literature, signs and symptoms of nephrotoxicity, such as cells and casts in the urine, oliguria, proteinuria, elevated serum creatinine, and elevated urea in humans, may occur in some individuals, especially patients with renal disease and these agents should be used cautiously with any patient having a history of renal disease. There might be an advantage to choosing minimum therapeutic doses of olanzapine and risperidone with chronic administration to decrease their side effects on the kidney in these special circumstances. Antioxidants or lipid peroxidation inhibitors also might provide nephroprotection in olanzapine-or risperidone-induced nephropathy, particularly in vulnerable patients. Large-scale prospective studies that will examine the association between nephrotoxicity and chronic use of olanzapine and risperidone are also needed in order to confirm the present findings.
CONCLUSION
Although no strong evidence suggests toxicity to the kidney during olanzapine or risperidone treatment, our data show that olanzapine is dose-dependently and risperidone is dose-independently toxic to rat kidney cells. However, we failed to compare our findings to a wide variety of studies, because no experimental study in the literature histopathologically investigated the effects of both olanzapine and risperidone on renal cells in the rats. Due to the fact that the mechanism of action of olanzapine and risperidone has not been fully elucidated and their exact nephrotoxic mechanism is still being investigated, additional specific experimental studies of rat kidneys exposed to olanzapine and risperidone may provide useful data about possible effects on renal cells.
Limitations
The present administration route (intraperitoneal) is different from the routine clinical route (oral or intramuscular) and makes extrapolation to humans more questionable, particularly in the absence of toxicokinetics/ metabolism. In addition, basic biological parameters might have been included, especially to evaluate the kidney functions (e.g. urea, creatinine, and potassium). Finally, macroscopic characteristics of the kidneys (e.g. shape, size, and weight) and general health of the animals (e.g. clinical status, appetite, and body weight) could have been considered.
